Highest Quality | For Research Use Only

Human C

Buy Human C Peptide Malta

Human C peptide, a short 31-amino acid polypeptide, is synthesized as a byproduct during the production of insulin in the pancreatic β-cells. The release ratio of insulin to C-peptide is almost 1:1 making it an important clinical marker for evaluating endogenous insulin secretion, particularly in type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM).

Human C peptide has shown promise in the treatment of diabetic complications. A series of clinical trials have suggested that C-peptide replacement therapy might be beneficial in patients with T1DM, improving renal function, nerve conduction, and microvascular blood flow.

Showing the single result

SALE

Human C
£8.99 – £17.97
Select options
This product has multiple variants. The options may be chosen on the product page

Potential Benefits of Human C Peptide

Proteinuria Reduction: Studies suggest that C-peptide may help reduce proteinuria (excess protein in the urine), a common symptom in patients with diabetic nephropathy [1].
Neuropathy Improvement: Clinical trials have shown that C-peptide replacement therapy can improve nerve conduction and reduce neuropathic symptoms in type 1 diabetes patients [2].
Vascular Health: There is research evidence to suggest that C-peptide has beneficial effects on the vascular system, potentially improving blood flow and decreasing inflammation [3].
Glycemic Control: Studies have shown in patients with type 1 diabetes, residual C-peptide has been associated with improved glycemic control and reduced incidence of severe hypoglycemia [4].
Prevention of Diabetes Complications: Studies have indicated that even marginal residual C-peptide secretion could have clinical benefits in type 1 diabetes, particularly in relation to hypoglycemia and microvascular complications [5].
Indicator of Pancreatic Beta Cell Function: C-peptide levels are used as an indicator of pancreatic beta cell function and insulin production, particularly in the diagnosis and management of diabetes [6].

References

[1] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC10512826/

[2] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC8000702/

[3] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC4317306/

[4] https://diabetesjournals.org/care/ article/35/3/465/28711/ Persistence of Prolonged C peptide Production in

[5] https://diabetesjournals.org/care/ article/44/2/390/35493/ Clinical Impact of Residual C-Peptide Secretion in

[6] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC9543865/

ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.

DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Direct Peptides website: https://malta.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.

Europe Malta